SOLID TUMORS HARBORING NTRK FUSION
Clinical trials for SOLID TUMORS HARBORING NTRK FUSION explained in plain language.
Never miss a new study
Get alerted when new SOLID TUMORS HARBORING NTRK FUSION trials appear
Sign up with your email to follow new studies for SOLID TUMORS HARBORING NTRK FUSION, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug shrinks tumors in patients with rare gene mutation
Disease control CompletedThis study tested the drug larotrectinib in 215 adults with various solid cancers that have a specific change in the NTRK gene. The drug is taken orally and works by blocking the action of the altered gene. The main goal was to see how many patients had their tumors shrink or dis…
Matched conditions: SOLID TUMORS HARBORING NTRK FUSION
Phase: PHASE2 • Sponsor: Bayer • Aim: Disease control
Last updated Jul 02, 2026 06:00 UTC
-
New pill targets rare gene in Hard-to-Treat cancers
Disease control CompletedThis study tested a new pill called larotrectinib in 75 adults with advanced cancers that have a specific gene change (NTRK fusion). The main goals were to check the drug's safety, find the best dose, and see how the body processes it. Participants had no other good treatment opt…
Matched conditions: SOLID TUMORS HARBORING NTRK FUSION
Phase: PHASE1 • Sponsor: Bayer • Aim: Disease control
Last updated Jun 27, 2026 09:02 UTC